title: Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
abstract: We evaluated the influence of baseline age, bone mineral density (BMD), and serum levels of vitamin D on the response to risedronate treatment. Risedronate consistently increased BMD, but our results suggest vitamin D supplementation may be necessary to achieve optimal treatment effect. Furthermore, early intervention may help prevent bone fractures.
  
  
  
  We aimed to investigate the influence of baseline age, BMD, and vitamin D insufficiency on the response to risedronate treatment.
  
  
  
  Data regarding 1447 patients was obtained from the registries of three phase III clinical trials of risedronate. The response to treatment was expressed in terms of BMD increase and occurrence of new vertebral fractures. The patients were stratified by baseline values for age (<65, 65-72, and ≥72 years), lumbar spine BMD T-score (osteoporotic, <-2.5; and non-osteoporotic, ≥- 2.5), and serum levels of 25-hydroxyvitamin D (deficient, <21 ng/mL; and non-deficient, ≥21 ng/mL).
  
  
  
  Risedronate consistently increased lumbar spine BMD in all the groups, with similar percentage and absolute increments in all the age tertiles. The percentage, but not absolute, increment in BMD was significantly higher (p = 0.0003) in the osteoporotic than that in the non-osteoporotic patients (baseline). Of the 1330 patients whose baseline serum levels of 25-hydroxyvitamin D were available, 44.7% had vitamin D deficiency (<20 ng/mL), while 89.2% had insufficiency (<30 ng/mL). The percentage and absolute increments in BMD were lower (p < 0.05 and p < 0.01, respectively) in the vitamin D-deficient than those in the non-deficient patients. New vertebral fractures occurred in 1.5 and 0.8% of the osteoporotic and non-osteoporotic patients, respectively (end of the treatment).
  
  
  
  Therapeutic response in elderly patients is consistent, but early initiation of risedronate treatment may help prevent fractures. Risedronate-induced increase in BMD is lower in patients with vitamin D deficiency, suggesting that vitamin D supplementation is important to achieve optimal treatment response.
authors.affiliation: Department of Orthopaedic Surgery, Hamanomachi Hospital, Fukuoka, Japan. mawtaro@gmail.com.|Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. mawtaro@gmail.com.
authors.forename: T
authors.identifier: 0000-0002-1909-5009
authors.initials: T
authors.lastname: Mawatari
authors.affiliation: Data Science Group, Clinical Development Department, EA Pharma Co., Ltd., Tokyo, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Muraoka
authors.affiliation: Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.|Department of Orthopaedic Surgery, Kyushu Rosai Hospital, Fukuoka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Iwamoto
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D058866:Osteoporotic Fractures / Q000209:etiology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D014808:Vitamin D Deficiency / Q000097:blood / Q000150:complications / Q000503:physiopathology
chemical_list: D050071:Bone Density Conservation Agents; D014807:Vitamin D; C104450:25-hydroxyvitamin D; D000068296:Risedronic Acid
keywords: Age; Bone mineral density; Osteoporosis; Risedronate; Treatment response; Vitamin D deficiency